Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 67,700 shares, an increase of 67.6% from the November 30th total of 40,400 shares. Based on an average trading volume of 311,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Price Performance

Sonoma Pharmaceuticals stock remained flat at $2.75 during midday trading on Friday. 39,192 shares of the company traded hands, compared to its average volume of 208,409. Sonoma Pharmaceuticals has a one year low of $2.44 and a one year high of $9.37. The stock has a market capitalization of $3.68 million, a P/E ratio of -0.55 and a beta of 1.43. The stock has a 50-day moving average of $2.78 and a two-hundred day moving average of $1.90.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.